{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:55Z","timestamp":1790821555368,"version":"4.1.0"},"reference-count":151,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100032441","name":"Immunic AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032441","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/13543784.2026.2705509","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:52:32Z","timestamp":1784206352000},"page":"565-579","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data"],"prefix":"10.1080","volume":"35","author":[{"given":"Matej","family":"Ondrus","sequence":"first","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[{"name":"Cleveland Clinic","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Peelen","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliano","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sciacca","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Sanchez-Gomez","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Arend","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Samcova","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gege","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesia","family":"Havrylova","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hella","family":"Kohlhof","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Tardio","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vitt","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Muehler","sequence":"additional","affiliation":[{"name":"Immunic AG","place":["Gr\u00e4felfing, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0B013E31829A3388"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00289-7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000279"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001045"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41582-021-00581-X"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.25197"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWF025"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2022.4655"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWAC111"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16289"},{"key":"e_1_3_5_13_1","unstructured":"Genzyme Corporation. Aubagio prescribing information. Cambridge (MA): Genzyme Corporation; 2012 [cited 2026 Jun 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202992s017lbl.pdf"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa052643"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010012"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1014656"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1114287"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1206328"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.17712\/NSJ.2018.3.20180003"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-018-9144-9"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40263-020-00700-0"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41582-019-0183-3"},{"key":"e_1_3_5_25_1","unstructured":"OCREVUS\u00ae (ocrelizumab) United States prescribing information. Published 2024 [cited 2024 Nov 26]. Available from: https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-019-09248-6"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/S13311-023-01415-Y"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70056-X"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/451912"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00154-0"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)12023-X"},{"key":"e_1_3_5_32_1","unstructured":"NOVANTRONE\u00ae (mitoxantrone) United States prescribing information. Published 2012 [cited 2025 Nov 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019297s033s034lbl.pdf"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000146958.77317.3E"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30069-3"},{"key":"e_1_3_5_35_1","unstructured":"Center for Drug Evaluation and Research. 209884Orig1s000 siponimod clinical review. [cited 2025 Dec 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/209884Orig1s000MedR.pdf"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415988"},{"key":"e_1_3_5_37_1","unstructured":"Center for Drug Evaluation and Research. 761053Orig1s000 \u2013 ocrelizumab medical review. [cited 2024 Nov 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761053orig1s000medr.pdf"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.21079"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01314-8"},{"key":"e_1_3_5_40_1","unstructured":"Complete Response Letter of the FDA: U.S. Food and Drug Administration. Complete response letter for tolebrutinib. NDA 219624. 2025 Dec 23 [cited 2026 Jun 28]. Available from: https:\/\/download.open.fda.gov\/crl\/CRL_NDA219624_20251223.pdf"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40120-023-00532-2"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1606468"},{"key":"e_1_3_5_43_1","unstructured":"European Medicines Agency. Ocrevus assessment report. [cited 2024 Nov 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/ocrevus-h-c-004043-x-0039-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00617-3"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000216067"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00027-9"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.10.021"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/S41120-016-0003-4"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00415"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00459"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE01645"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PNEUROBIO.2005.09.001"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1509742112"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-023-39970-9"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2009.01.038"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/MDS.20820"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/NG1066"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/ACEL.12866"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3910-09.2009"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.95.7.4013"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-67549-7"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1270256"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6843265"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/CNS.12825"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.272427"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416184"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/S13024-022-00544-W"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20194858"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/BRAINCOMMS\/FCAD072"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/ARCHNEUROL.2011.32"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0008962"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390501"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JMEDCHEM.2C00585"},{"key":"e_1_3_5_74_1","volume-title":"Poster presented at: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), ePoster number: P1410","author":"Peelen E","year":"2024","unstructured":"Peelen E, Wu H, Marschner J, et al. Vidofludimus calcium activity on Nurr1 in preclinical models: a potential neuroprotective function in multiple sclerosis. Poster presented at: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), ePoster number: P1410; 2024 Sep 18\u201320; Copenhagen, Denmark. Available from: https:\/\/imux.com\/wp-content\/uploads\/2024\/09\/20240918_Immunic_Poster-ECTRIMS-2024_Vidofludimus_Calcium_Activity_on_NURR1_in_Preclinical_Models.pdf"},{"key":"e_1_3_5_75_1","volume-title":"Poster presented at: 16th International Congress of Neuroimmunology (ISNI), abstract number: 252","author":"Peelen E","year":"2023","unstructured":"Peelen E, Vietor J, Gege C, et al. Vidofludimus calcium, an orally available DHODH inhibitor in phase 3 clinical trials for multiple sclerosis, potently activates NURR1. Poster presented at: 16th International Congress of Neuroimmunology (ISNI), abstract number: 252; 2023 Aug 23; (QC), Canada. Available from: https:\/\/imux.com\/wp-content\/uploads\/2023\/08\/20230816_ISNI2023_Final.pdf"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.34.21682"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027547"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri853"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.50.29682"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE09882"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24219"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAO5563"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24054296"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-014-0212-X"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/CMDC.202400292"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.VIRS.2023.11.006"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/JMV.29372"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27891"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/v12080821"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102129"},{"key":"e_1_3_5_91_1","volume-title":"Poster presented at: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), ePoster number: P1390","author":"Peelen E","year":"2024","unstructured":"Peelen E, Ohara D, Takeuchi Y, et al. Vidofludimus calcium shows T helper cell modulatory effects in murine experimental autoimmune encephalomyelitis: one of the potential mode of action pathways for MS treatment. Poster presented at: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), ePoster number: P1390; 2024 Sep 18\u201320; Copenhagen, Denmark. Available from: https:\/\/imux.com\/wp-content\/uploads\/2024\/09\/20240918_Immunic_Poster-ECTRIMS-2024_Vidofludimus_Calcium_Shows_T_Helper_Cell_Modulatory_Effects_in_Murine_Experimental_Autoimmune_Encephalomyelitis.pdf"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.2353\/AJPATH.2010.091227"},{"key":"e_1_3_5_93_1","volume-title":"Talk presented at: B&T Cell-Mediated Autoimmune Disease Drug Development Summit","author":"Peelen E","year":"2021","unstructured":"Peelen E. IMU-838: a safe and potent inhibitor of DHODH for the treatment of autoimmune disease: mechanism of action and clinical outcomes. Talk presented at: B&T Cell-Mediated Autoimmune Disease Drug Development Summit; 2021 Oct 6; Virtual. https:\/\/imux.com\/wp-content\/uploads\/2021\/10\/20211006_Immunic_2021_Virtual_BT_cell_mediated_Autoimmune_disease_drug_development_summit_Final.pdf"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102218"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANTIVIRAL.2024.106043"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/v12121394"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40121-022-00690-0"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.ABJ8222"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0B013E3181AA29FE"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000190"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MICPATH.2023.106031"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-022-04432-7"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20220650"},{"key":"e_1_3_5_104_1","volume-title":"Poster presented at: 37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","author":"Marschall M","year":"2021","unstructured":"Marschall M, Peelen E, M\u00fcller R, et al. IMU-838, a small molecule DHODH inhibitor in phase 2 clinical trial for multiple sclerosis, shows potent anti-EBV activity in cell-culture-based systems: potential additional benefits in multiple sclerosis treatment. Poster presented at: 37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2021 Oct 13\u201315; Virtual. https:\/\/imux.com\/wp-content\/uploads\/2021\/10\/Immunic_Poster_ECTRIMS_2021_MS-EBV_Data.pdf"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.178"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20071030"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2019.01.011"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2076901"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10060763"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-021-90351-Y"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJID.2020.12.051"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15471"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/BRAINCOMMS\/FCAE278"},{"issue":"1","key":"e_1_3_5_114_1","first-page":"15","article-title":"Chronic fatigue syndrome, depression, and anxiety symptoms due to relapsing-remitting multiple sclerosis are associated with reactivation of Epstein-Barr virus and Human Herpesvirus 6","volume":"46","author":"Maes M","year":"2025","unstructured":"Maes M, Almulla AF, Vojdani E, et al. Chronic fatigue syndrome, depression, and anxiety symptoms due to relapsing-remitting multiple sclerosis are associated with reactivation of Epstein-Barr virus and Human Herpesvirus 6. Neuro Endocrinol Lett. 2025;46(1):15\u201326. PMID: 40319455.","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30354-9"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JNS.2017.07.042"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-020-00623-7"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200208"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00286-z"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/ACN3.51574"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-025-09008-0"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2021-055205"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.14309\/CTG.0000000000000813"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/HEP4.1926"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70102-9"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61619-0"},{"key":"e_1_3_5_128_1","volume-title":"Poster presented at: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023, poster ID: DMT51","author":"Fox R","year":"2023","unstructured":"Fox R, Wolf C, Sciacca V, et al. Assessment of long-term safety and tolerability of vidofludimus calcium in patients with relapsing remitting multiple sclerosis in the open-label extension period of the phase 2 trial (EMPhASIS). Poster presented at: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023, poster ID: DMT51; 2023 Jun 1; Aurora, CO. Available from: https:\/\/ir.imux.com\/image\/20230503_CMSC+2023+Poster_Final.pdf"},{"key":"e_1_3_5_129_1","volume-title":"Poster presented at: ECTRIMS 2025","author":"Fox R","year":"2025","unstructured":"Fox R, Sciacca V, Ondrus M, et al. 144-week analysis of the confirmed disability worsening events in the open-label treatment extension of the phase 2 EMPhASIS study of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis. Poster presented at: ECTRIMS 2025; 2025 Sep 24\u201326; Barcelona, Spain. Available from: https:\/\/imux.com\/wp-content\/uploads\/2025\/09\/20250925-ECTRIMS-144-Week-Analysis-of-the-Confirmed-Disability-Worsening-Events-Emphasis.pdf"},{"key":"e_1_3_5_130_1","volume-title":"Talk presented at: 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Presentation ID O024","author":"Fox RJ","year":"2025","unstructured":"Fox RJ, Wolf C, Nastaj M, et al. Efficacy and safety of vidofludimus calcium, a novel Nurr1 activator and selective DHODH inhibitor, in progressive multiple sclerosis: data from the phase 2 CALLIPER trial. Talk presented at: 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Presentation ID O024; 2025 Sep 24\u201326; Barcelona, Spain. Available from: https:\/\/imux.com\/wp-content\/uploads\/2025\/09\/20250924-ECTRIMS-Efficacy-and-Safety-of-Vidofludimus-Calcium-in-Progressive-Multiple-Sclerosis-Calliper.pdf"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0210417"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JOCN.2016.02.041"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2015.11.006"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40120-018-0107-Y"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRC1970"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2018027227"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)81704-4"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-61571-5"},{"key":"e_1_3_5_139_1","volume-title":"Poster presented at: ECTRIMS 2025","author":"Fox R","year":"2025","unstructured":"Fox R, Dokova Y, Wolf C, et al. Update on the assessment of long-term safety and tolerability of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis in the open-label extension period of the phase 2 EMPhASIS trial. Poster presented at: ECTRIMS 2025; 2025 Sep 24\u201326; Barcelona, Spain. Available from: https:\/\/imux.com\/wp-content\/uploads\/2025\/09\/20250925-ECTRIMS-Update-assessment-of-long-term-safety-and-tolerability-of-vidofludimus-calcium-Emphasis.pdf"},{"key":"e_1_3_5_140_1","unstructured":"Immunic AG. Study to evaluate the efficacy safety and tolerability of IMU-838 in patients with relapsing multiple sclerosis (ENSURE-1). ClinicalTrials.gov identifier: NCT05134441. Updated 2024 Apr 18."},{"key":"e_1_3_5_141_1","unstructured":"Immunic AG. Study to evaluate the efficacy safety and tolerability of IMU-838 in patients with relapsing multiple sclerosis (ENSURE-2). ClinicalTrials.gov identifier: NCT05201638. Updated 2024 Apr 18."},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518799598"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208006"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRNEUROL.2016.21"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333206"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26309"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40120-019-0127-2"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217317725102"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.18553\/JMCP.2017.23.8.844"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S452849"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1468-1331.2010.03110.X"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419836571"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616634247"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2705509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2705509","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2705509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:31:36Z","timestamp":1787826696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2705509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":151,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/13543784.2026.2705509"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2705509","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}